Creative Financial Designs’s Alnylam Pharmaceuticals ALNY Stock Holding History

Creative Financial Designs’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$987	Buy	4 +3	+300%	+$763	﹤0.01%	2130
2026 Q2	$301	Hold	1	–	–	﹤0.01%	2179
2026 Q1	$331	Sell	1 -1	-50%	-$340	﹤0.01%	2039
2025 Q4	$795	Hold	2	–	–	﹤0.01%	1837
2025 Q3	$912	Buy	2 +1	+100%	+$407	﹤0.01%	1823
2025 Q2	$326	Hold	1	–	–	﹤0.01%	1915
2025 Q1	$270	Buy	+1	New	+$257	﹤0.01%	1961

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Creative Financial Designs's ALNY Position: Q3 2026 in Review

Creative Financial Designs increased its Alnylam Pharmaceuticals (ALNY) stake by 300% in Q3 2026, buying an estimated $763 and bringing the position to 4 shares worth $987. The position accounts for ﹤0.01% of the portfolio, ranked #2130.

Creative Financial Designs first reported a position in ALNY in Q1 2025 and has held it in 7 quarters since. 403 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

Creative Financial Designs held 4 shares of Alnylam Pharmaceuticals worth $987 as of Q3 2026.
Creative Financial Designs bought 3 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $763.
Alnylam Pharmaceuticals made up ﹤0.01% of Creative Financial Designs's portfolio in Q3 2026, its #2130 holding.
Creative Financial Designs first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
403 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Creative Financial Designs's 13F filing for Q3 2026, filed 4 Nov 2026.